Regulatory response to drugmaker woes not expected to slow biotech growth

01/3/2005 | Bloomberg Businessweek

The troubles experienced by several companies in the pharmaceutical industry this past year have left biotech investors concerned the FDA will have to clamp down on safety problems affecting biotech firms along with drugmakers. Nonetheless, Ernst & Young International foresees no slowdown in sales of biotech drugs and vaccines, with industry revenues expected to rise to $51.4 billion this year, a 19.5% increase over revenues expected to be reported for 2004.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA